EUVIMEDEUVIMED entdecken
Crossref

Association Between Inflammatory Markers, Comorbidities, and Mortality in COVID‐19 Patients Treated With Tocilizumab

Rafaela Munari da Silva, Mauricio Santiago Soper, Juliana Haider Neves, Carlos Emanuel Antunes Maciel, Matheus Eduardo de Melo, Arthur Pille, Juçara Gasparetto Maccari, Mohamed Parrini Mutlaq, Luiz Antônio Nasi, Jonas Michel Wolf iD

Journal of Medical Virology · 2026-06 · 98 (6)

DOI: 10.1002/jmv.71028 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, online erschienen am 22.06.2026. Verfasst von Rafaela Munari da Silva und 9 weiteren Autor:innen. Beteiligte Einrichtung: Escritório de Gestão da Prática clínica, Hospital Moinhos de Vento, Porto Alegre, Rio Grande do Sul, Brasil. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, COVID-19 Drug Treatment, COVID-19, Inflammation. Die Arbeit nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tocilizumab, an interleukin‐6 receptor antagonist, has been widely used in the management of severe COVID‐19 cases, but its clinical outcomes have been variable. A retrospective cohort including 113 hospitalized adult patients with confirmed COVID‐19 treated with tocilizumab between March and October 2021 at a private hospital in southern Brazil. Demographic, clinical, and laboratory variables were collected at four time points: admission, 72 h before tocilizumab administration, 72 h after, and at hospital discharge or death. The median age was significantly higher among non‐survivors (73.0 vs. 58.5 years; p < 0.01). Cardiovascular, metabolic, pulmonary, and neoplastic comorbidities negatively impacted clinical outcomes. These patients also showed persistent elevation of inflammatory markers and organ dysfunction indicators, such as d ‐dimer, urea, and BNP. Concomitant use of corticosteroids was associated with improved survival ( p = 0.04). Age, comorbidities, and persistent elevation of inflammatory markers were associated with worse prognosis in patients treated with tocilizumab. Concomitant use of corticosteroids demonstrated a potential benefit, suggesting a synergistic effect between the therapies. These findings underscore the importance of laboratory monitoring and individualized therapeutic approaches in severe COVID‐19.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedCOVID-19 Drug TreatmentCOVID-19InflammationHumansFemaleMiddle AgedRetrospective StudiesMaleAgedBiomarkersComorbiditySARS-CoV-2PrognosisAged, 80 and overBrazilAdrenal Cortex HormonesTreatment Outcome

Stichwörter der Autor:innen

COVID‐19corticosteroidsprognosistherapeutictocilizumab

Substanzen

Antibodies, Monoclonal, HumanizedtocilizumabBiomarkersAdrenal Cortex Hormones

Autor:innen und Institutionen

  • Escritório de Gestão da Prática clínica, Hospital Moinhos de Vento, Porto Alegre, Rio Grande do Sul, Brasil.
  • Faculdade de Ciências da Saúde Moinhos de Vento, Porto Alegre, Rio Grande do Sul, Brasil.
  • Gerencia médica, Hospital Moinhos de Vento, Porto Alegre, Rio Grande do Sul, Brasil.
  • Superintendente executivo, Hospital Moinhos de Vento, Porto Alegre, Rio Grande do Sul, Brasil.
  • Superintendente médico, Hospital Moinhos de Vento, Porto Alegre, Rio Grande do Sul, Brasil.
  • Núcleo de Apoio à Pesquisa, Hospital Moinhos de Vento, Porto Alegre, Rio Grande do Sul, Brasil.

ORCID-Profile: Jonas Michel Wolf

Zitieren

APA

Silva, R. M. D., Soper, M. S., Neves, J. H., Maciel, C. E. A., de Melo, M. E., Pille, A., Maccari, J. G., Mutlaq, M. P., Nasi, L. A., & Wolf, J. M. (2026). Association Between Inflammatory Markers, Comorbidities, and Mortality in COVID‐19 Patients Treated With Tocilizumab. Journal of Medical Virology, 98(6). https://doi.org/10.1002/jmv.71028

Vancouver

Silva RMD, Soper MS, Neves JH, Maciel CEA, de Melo ME, Pille A, et al. Association Between Inflammatory Markers, Comorbidities, and Mortality in COVID‐19 Patients Treated With Tocilizumab. Journal of Medical Virology. 2026;98(6). doi:10.1002/jmv.71028

BibTeX
@article{Silva2026,
  author = {Silva, Rafaela Munari da and Soper, Mauricio Santiago and Neves, Juliana Haider and Maciel, Carlos Emanuel Antunes and de Melo, Matheus Eduardo and Pille, Arthur and Maccari, Juçara Gasparetto and Mutlaq, Mohamed Parrini and Nasi, Luiz Antônio and Wolf, Jonas Michel},
  title = {Association Between Inflammatory Markers, Comorbidities, and Mortality in COVID‐19 Patients Treated With Tocilizumab},
  journal = {Journal of Medical Virology},
  year = {2026},
  volume = {98},
  number = {6},
  doi = {10.1002/jmv.71028}
}
Kostenlos starten →